论文部分内容阅读
目的:探讨哌拉西林舒巴坦与莫西沙星联用治疗社区获得性肺炎的临床效果。方法:随机选取2015年3月--2016年3月在我院呼吸科病区住院的90例社区获得性肺炎患者,并随机分为观察组(28例)、对照A组(31例)对照B组(31例)。观察组患者采用哌拉西林舒巴坦粉针3.75 g,bid,联合莫西沙星0.4 g,静脉注射,qd,对照A组患者则单用哌拉西林舒巴坦粉针3.75 g,静脉滴注,bid,对照B组患者采用单用莫西沙星0.4 g,静脉注射,qd,三组患者的治疗时间均为10 d。治疗结束后,比较两组患者的临床症状改善情况及不良反应的发生情况。结果:治疗10天后,观察组患者治疗后肺部浸润性阴影、肺部啰音、胃肠道情况及体温等均显著好转,观察组患者的临床治疗有效情况显著高于对照A组(100%vs 87.09%,P<0.05),对照B组的有效率也较A组提高(96.77%vs 87.09%,P>0.05)。观察组总体治愈率显著高于对照A组(92.86%vs 51.61%),对照B组的总体治愈率显著高于对照A组(70.97%vs 51.61%),但观察组和对照B组之间并无显著性差异(p>0.05)。观察组、对照A组、对照B组的细菌清除率分别为92.86%、74.19%、90.32%,观察组和对照B组的清除率显著高于对照A组;三组的不良反应发生率比较并无显著性差异(P>0.05)。结论:哌拉西林舒巴坦联合莫西沙星治疗社区获得性肺炎的效果显著优于单用哌拉西林舒巴坦治疗的效果,稍优于单用莫西沙星的治疗效果,安全性较高。
Objective: To investigate the clinical efficacy of piperacillin-sulbactam combined with moxifloxacin in the treatment of community-acquired pneumonia. Methods: Ninety patients with community-acquired pneumonia who were hospitalized in our hospital respiratory department ward from March 2015 to March 2016 were randomly selected and randomly divided into observation group (n = 28) and control group A (n = 31) Group B (31 cases). Patients in the observation group were given piperacillin sulbactam powder (3.75 g, bid) and moxifloxacin 0.4 g intravenously, qd, while in control group A, patients were given piperacillin and sulbactam powder alone 3.75 g intravenously , bid, the control group B patients with single moxifloxacin 0.4 g, intravenous injection, qd, three groups of patients were treated for 10 d. After the treatment, the improvement of clinical symptoms and the occurrence of adverse reactions in both groups were compared. Results: After treatment for 10 days, the lung infiltration shadow, pulmonary rales, gastrointestinal tract and body temperature in the observation group were significantly improved after treatment. The clinical treatment efficacy in the observation group was significantly higher than that in the control group A (100% vs 87.09%, P <0.05). The effective rate of control group B was also higher than that of group A (96.77% vs 87.09%, P> 0.05). The overall cure rate in observation group was significantly higher than that in control group A (92.86% vs 51.61%). The overall cure rate in control group B was significantly higher than that in control group A (70.97% vs 51.61%), but the observation group and control group B No significant difference (p> 0.05). The bacterial clearance rates of the observation group, the control group A and the control group B were 92.86%, 74.19% and 90.32% respectively, and the clearance rates of the observation group and the control group B were significantly higher than those of the control group A; the incidences of adverse reactions in the three groups were No significant difference (P> 0.05). Conclusion: The efficacy of piperacillin-sulbactam and moxifloxacin in the treatment of community-acquired pneumonia was significantly better than that of piperacillin-sulbactam alone, which was slightly better than that of moxifloxacin alone, with higher safety .